| scholarly article | Q13442814 |
| P2093 | author name string | Middleton S | |
| Levin J | |||
| Levi M | |||
| de Groot PG | |||
| Harris R | |||
| ten Cate JW | |||
| Biemond BJ | |||
| Friederich PW | |||
| Heijnen HF | |||
| Wu YP | |||
| P2860 | cites work | Shortening of the Bleeding Time in Rabbits by Hydrocortisone Caused by Inhibition of Prostacyclin Generation by the Vessel Wall | Q33456363 |
| Prophylactic Platelet Transfusions in Children with Acute Leukemia: A Dose Response Study | Q33466322 | ||
| The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. | Q33501152 | ||
| Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions | Q33501221 | ||
| A critical reappraisal of the bleeding time | Q38143842 | ||
| Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis | Q46779718 | ||
| The risk of transfusion-transmitted infection | Q68198045 | ||
| Thrombogenicity of vascular cells. Comparison between endothelial cells isolated from different sources and smooth muscle cells and fibroblasts | Q68795347 | ||
| New Variant of Human Tissue Plasminogen Activator (TPA) With Enhanced Efficacy and Lower Incidence of Bleeding Compared With Recombinant Human TPA | Q71807529 | ||
| Aggregate formation is more strongly inhibited at high shear rates by dRGDW, a synthetic RGD-containing peptide | Q72862076 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | thrombocytopenia | Q585285 |
| P304 | page(s) | 107-111 | |
| P577 | publication date | 1999-01-01 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits | |
| P478 | volume | 5 |
| Q45868696 | A novel approach to improving recombinant factor VIIa activity with a preserved platelet preparation |
| Q98292398 | A polymer-based systemic hemostatic agent |
| Q33433352 | A swine model of acute thrombocytopenia with prolonged bleeding time produced by busulfan |
| Q39190309 | Airflow-directed in situ electrospinning of a medical glue of cyanoacrylate for rapid hemostasis in liver resection |
| Q33435484 | Alternatives to allogeneic platelet transfusion. |
| Q33785932 | Alternatives to standard blood transfusion: availability and promise |
| Q39179984 | Bio-inspired nanomedicine strategies for artificial blood components |
| Q47324534 | Biomaterials and Advanced Technologies for Hemostatic Management of Bleeding. |
| Q60998516 | Engineering Intravenously Administered Nanoparticles to Reduce Infusion Reaction and Stop Bleeding in a Large Animal Model of Trauma |
| Q90697102 | Engineering blood cells and proteins as blood substitutes: A short review |
| Q56365154 | Enhancing clot properties through fibrin-specific self-cross-linked PEG side-chain microgels |
| Q26829998 | Fibrinogen and fibrin based micro and nano scaffolds incorporated with drugs, proteins, cells and genes for therapeutic biomedical applications |
| Q33402878 | Fibrinogen γ-chain peptide-coated, ADP-encapsulated liposomes rescue thrombocytopenic rabbits from non-compressible liver hemorrhage. |
| Q37278074 | Hemostatic Nanoparticles Improve Survival Following Blunt Trauma Even after 1 Week Incubation at 50 °C. |
| Q33367016 | Hemostatic effects of fibrinogen gamma-chain dodecapeptide-conjugated polymerized albumin particles in vitro and in vivo |
| Q33348326 | Hemostatic effects of polymerized albumin particles bearing rGPIa/IIa in thrombocytopenic mice |
| Q38168784 | Hemostatic strategies for traumatic and surgical bleeding |
| Q41215308 | Intravenous hemostatic nanoparticles increase survival following blunt trauma injury |
| Q38148673 | Intravenous hemostats: challenges in translation to patients |
| Q30584438 | Intravenously administered nanoparticles increase survival following blast trauma |
| Q33437439 | In vitro characterization of SynthoPlate™ (synthetic platelet) technology and its in vivo evaluation in severely thrombocytopenic mice |
| Q33401554 | Liposomes bearing fibrinogen could potentially interfere with platelet interaction and procoagulant activity |
| Q93926542 | Literature alerts |
| Q35796487 | Management of Jehovah's Witness patients with haematological problems |
| Q33373596 | New strategy of platelet substitutes for enhancing platelet aggregation at high shear rates: cooperative effects of a mixed system of fibrinogen gamma-chain dodecapeptide- or glycoprotein Ibalpha-conjugated latex beads under flow conditions |
| Q91339121 | Novel platelet products under development for the treatment of thrombocytopenia or acute hemorrhage |
| Q33338494 | Novel platelet products, substitutes and alternatives |
| Q33338937 | Novel treatment modalities: new platelet preparations and substitutes |
| Q33334939 | Platelet substitutes and novel platelet products |
| Q90422944 | Platelet transfusion: Current challenges |
| Q34579964 | Platelet-like nanoparticles: mimicking shape, flexibility, and surface biology of platelets to target vascular injuries |
| Q33375630 | Prolonged hemostatic ability of polyethylene glycol-modified polymerized albumin particles carrying fibrinogen gamma-chain dodecapeptide |
| Q34434805 | Revisitation of the clinical indications for the transfusion of platelet concentrates |
| Q44100697 | Rolling properties of rGPIbalpha-conjugated phospholipid vesicles with different membrane flexibilities on vWf surface under flow conditions |
| Q77501894 | Splenic clearance mechanisms of rehydrated, lyophilized platelets |
| Q33349074 | Substitutes and alternatives to platelet transfusions in thrombocytopenic patients |
| Q77779188 | Substitutes for success |
| Q35858739 | Synthetic Strategies for Engineering Intravenous Hemostats |
| Q33433930 | Thrombocytopenia-Platelet Support or Growth Factors? |
| Q78639201 | Thrombus formation with rehydrated, lyophilized platelets |
| Q36647460 | Toward 21st century blood component replacement therapeutics: artificial oxygen carriers, platelet substitutes, recombinant clotting factors, and others |
| Q42579276 | Tuning ligand density on intravenous hemostatic nanoparticles dramatically increases survival following blunt trauma |
| Q27026630 | Vascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigm |
Search more.